# Polpharma — media coverage

Polpharma was mentioned 15 times in 2 outlets over the last 12 months. Positive (7%) and negative (0%) coverage were close.

- Data as of: 2026-10-04 (window: last 365 days)
- Mentions (12 months): 15 (22 all-time)
- Outlets (12 months): 2 in 2 countries
- Average sentiment: +0.064 (7% positive, 0% negative)
- Sector: Pharma
- Also written as: Polpharma Group, Polpharma S.A.

## Coverage over time (mentions per month)

| Month | Mentions |
|---|---|
| 2025-11 | 1 |
| 2025-12 | 2 |
| 2026-01 | 0 |
| 2026-02 | 1 |
| 2026-03 | 1 |
| 2026-04 | 2 |
| 2026-05 | 4 |
| 2026-06 | 1 |
| 2026-07 | 1 |
| 2026-08 | 0 |
| 2026-09 | 0 |
| 2026-10 | 0 |

## Share of voice among Pharma peers (12 months)

| Brand | Mentions |
|---|---|
| Eli lilly | 130 |
| Astrazeneca | 78 |
| Pfizer | 64 |
| Johnson & johnson | 59 |
| Novo nordisk | 46 |
| Merck | 44 |
| Sandoz | 41 |
| Moderna | 38 |
| Bayer | 36 |
| Roche | 36 |

## Recent coverage

- [CMS advises Polpharma on landmark acquisition of Biofarm through voluntary takeover bid - CMS.law](https://cms.law/en/cze/news-information/cms-advises-polpharma-on-landmark-acquisition-of-biofarm-through-voluntary-takeover-bid) — cms.law, 2026-07-21, positive
- [Polpharma Biologics, Tuteur ink deal for autoimmune diseases biosimilar - Drug Store News](https://news.google.com/rss/articles/CBMilwFBVV95cUxNall4c3BLOW04dW9oRm80UUx1czRPXzhoTDRjUDNUZjVTcDBZMkxfUUUyZDNXX2ZqRXM3QTlYdHVKTDRCLUpnbUZfenZrTExqT1hmZTRHcW8tT1ByWmpKc1FaWHdxSnFOOHljWllrT0xqZmtGRVlnTkdib3dFcHZKTmdWeHhKaXN4RVRqMjhZQXg2RFFtQmY4?oc=5) — , 2026-06-01, neutral
- [Polpharma Biologics And Tuteur Sign Landmark LATAM Biosimilar Licensing Partnership - BioPharma APAC](https://news.google.com/rss/articles/CBMixgFBVV95cUxOaW9zaG9GV3l5djJ3b2NmWktoTFpvbHV2N1RjTG9BWWs3bXY0T2NyQVBxbk9SQ3dEQ0gxa0l1UzVFdGtWVUtiNmFLa09UdGhBYUNHZ2l6OGJRdm8wc3J6RmVwaW8xcUZ0Z044aG1iWU1qcnhZTVhNQWo4XzJ3T1puM2FQU1RfajNOXzZ2X1dJM3BqZXotalVtYmgzUHJhQk84aV9tRTFYUHlyNDVrRHVqSW9WRkRxZE5LVjVBRGpYLWxGVEl2M2c?oc=5) — , 2026-05-24, neutral
- [Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases - Business Wire](https://news.google.com/rss/articles/CBMi6AFBVV95cUxOc3NYWWFJY091OHdyVVMxbjhaRlpXeWxQX1JxMmt0QXRKYy00Tk9LbXpxODFyaWVqSHIxempwX3BaQzdyU1kyZzY3dHhBV1JyUHVMUFpTZDAwUzNieDlzcjNKVmtfM3hXbVU2QUYwV01EaFVCZzBEQkpiRWJvT0F5UnBiTEl5aXNoc2VlTXdsd2JscVJaSldYcWljNWRCV1VuREU1RTNfZnpNQ3FLaXU0YmVYaGgtQnJVNDkyRUVneTQ4eFBsUE81V3JNbnRTdkNYOFE3SEJWeVhSOG9vMVpfdUxmNmQ2TVdz?oc=5) — , 2026-05-22, neutral
- [Largest Polish pharma group Polpharma to take over Romania’s Biofarm at EUR 270 mln valuation - Romania Insider](https://news.google.com/rss/articles/CBMidkFVX3lxTE1BWEEycHRFU2ZRZnBPUGNDOVBlU21DN1prNzdIaFozZzVkNEt5UEtzRng1LUlMc0g3eEkxczNQdDVlSXNVbzlkZUVhOU9rWmt0VXdHcFlMMFlWMWpzNVhYcG9tV2F5MmNjY3RWd1dPTVRlZ2c5bXfSAXtBVV95cUxPLUc5TzF2YjktN1FLbEhnemwtQUdWRWxtOE54M1RXQk1SaVpQVlJaR2FNeTRKdy01MWFUc1dfZ2FEeWFlT0RLNVI2UXlYblpwaFVfeW1YbkZ5WXJrZWRxWmhoVVR5R2Nua0s2alBxX25zMjJBNmI2cWhxcUk?oc=5) — , 2026-05-07, neutral
- [Polpharma SA Pharmaceutical Works proposed to acquire Biofarm S.A. from Longshield Investment Group SA, Lion Capital S.A. and other shareholders for RON 1.4 billion. - marketscreener.com](https://news.google.com/rss/articles/CBMi5gFBVV95cUxPc0huQ0xmM3FkajVpdHNkV2VYUVROTzVKWmxoc3prS1hySGNzcXhuNmVXWDZ6cmdndXJyMEwtV2ZEcTBPaS1JdFVoZ2ZvOUdka3V4UVI1czJnWUFkZVBGZGp0TlFLRFJQeE9aV1FvRnhkY0ozR3lSTV9jWFRsZXA2cjdFMVMyYVlHR1lZeUJyOFhvZ0N3NjZreHQyR2ZRZWZ1c2RwMlRaZVR3SUQ4Nkxtcy11RHYtcFVXT19rYWtCU1VKTktGWmJtZHpUZHZ0X3d0UFdXMUJ5UTBIWUk2dmZ2ZnhOU1dwZw?oc=5) — , 2026-05-05, neutral
- [Striving for operational resiliency, Polpharma implements analytics at scale - KPMG](https://news.google.com/rss/articles/CBMiugFBVV95cUxNSGUzSFUzRDhNdEc2aHFlSkh3bzhvYm14aERzNUF3R0JVdHEzSmd3ODdtZG1WTEd5NVBqdXhjcURwSlhEMlcxcWlPOTRnVVVGSnAzaURrNFJWRFJENmN0WjV5alk2UHdxaVh4OEdrVWdPLVV0cUhPVG1GVkRyc1FaMVpvblA1ZVVMV1RGaFJjY3hiZkw2TTF5Vmo0cUl5VWtfU3VXOTR0VHRYQmw5Y09DY2x6NVFjNzRUY3c?oc=5) — , 2026-04-30, neutral
- [Russian drugmaker Binnopharm hopes to gain control over Polpharma’s Akrikhin - The Pharma Letter](https://news.google.com/rss/articles/CBMivwFBVV95cUxNSHlLNU1uSGdwZVVOVkIzRkxLU19DRDIxa2prUjY0ekhONXQxeTJ0a0RMMG1oYWZRUGFkZlJuLVVweWxkZnJpVGlmUDBVRXVOdkJLX05UMzQ4UUl4OUNHUkhPdXYzYkpqekE5NlJYc3ZMM3EwbDFiQmI0eUtjVlNOelBXdGMwX2VXVlhmNmh6RFYwWERpbTRSLVJuWkxHYjV1TkNzVmF6V0lVS3FDOEJQdk1VUGJWWEw2OHNhWlFBQQ?oc=5) — , 2026-04-14, neutral

Data: VoilàIQ, 2026-10-04. Canonical: https://voilaiq.com/brand-catalog/polpharma